Group 1 - Heng Rui Medicine has set the final price for its H-share issuance at HKD 44.05 per share, with expected listing on May 23, 2025 [1] - Vanke A has signed a borrowing contract with Shenzhen Metro Group for RMB 4.2 billion, using up to RMB 6 billion of Wanwu Cloud stock as collateral [2] - Longqi Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international competitiveness [3] Group 2 - Shanghai Laishi's controlling shareholder, Haiyingkang, plans to increase its stake in the company by investing between RMB 250 million and RMB 500 million [4] - Wangzi New Materials' controlling shareholder sold 1.11 million shares, accounting for 0.29% of the total share capital, amid the "controlled nuclear fusion" concept [5] - Huashi Technology's actual controller, Ye Jianbiao, has had his detention extended by three months, but the company's operations remain normal [6] Group 3 - Sichuan Gold's major shareholders plan to reduce their stakes by 2.5% and 3% respectively, citing personal funding needs [7] - Naxinwei has set the inquiry transfer price at RMB 163.15 per share, with full subscription from institutional investors [8] - Zhejiang Rongtai plans to invest RMB 20 million to establish a wholly-owned subsidiary focused on robotics [9] Group 4 - Kingood Co. has received a notification from a global leading automaker for a wheel product project in the U.S., with an estimated sales amount of approximately USD 158 million over five years [10] - Shanghai Xiba plans to purchase patents for hydrogen-electric hybrid power systems and solid-state lithium-ion battery technology, investing a total of RMB 25 million [11] - Nocare Biopharma's application for the market approval of Tafasitamab for treating relapsed/refractory DLBCL has been approved, marking a significant milestone in the market [12]

平治信息(300571.SZ)公告称，公司与 中国移动通信有限公司签订《中国移动2025年城区及农村基站天 线产品(补充采购)集中采购框架协议》，合同最高含税金额约为1301万元。该合同为平治信息日常经营 合同，对上市公司本年度业绩不会产生重大影响。 ...